{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T09:54:21Z","timestamp":1770285261154,"version":"3.49.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Heartburn and acid regurgitation are main symptoms of gastro-esophageal reflux, a widespread complaint with a significant impact on quality of life (QoL). <jats:italic>Refluthin\u00ae for Heartburn<\/jats:italic> chewable tablets (Refluthin) are a symptomatic treatment option containing a combination of an antacid (CaCO<jats:sub>3<\/jats:sub>, MgCO<jats:sub>3<\/jats:sub>) and a polysaccharide-rich extract with mucoprotective substances from <jats:italic>Opuntia ficus-indica<\/jats:italic> cladodes. To investigate performance and safety of Refluthin in the rapid and long lasting relief of heartburn and acid related gastric discomfort under practical use conditions, a prospective, clinical, uncontrolled, open-label study was conducted. Adults with symptomatic heartburn, acid regurgitation, and\/or recurrent acid related gastric discomfort took one tablet Refluthin up to four times\/day as needed for up to 4\u00a0weeks. Endpoints were both time to onset and duration of symptom relief; reflux symptom intensity\/frequency; global assessments (QoL, performance, satisfaction, usability, tolerability); and safety. 81\/100 participants (81%) responded with a first symptom relief within\u2009\u2264\u200920\u00a0min in\u2009\u2265\u200950% of the individual applications. Long lasting effects of\u2009&gt;\u2009120\u00a0min were reported by 83\/100 (83%) participants. Significant reductions in heartburn event frequency and intensity were seen within the 4\u00a0weeks of intermittent use (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001, respectively). Global assessment results and safety-relevant findings were also favorable. Results thus demonstrated a distinct rapid and long lasting symptom relief after intake of Refluthin, with a safe and easy use. The significant reductions in frequency and intensity of heartburn events over time indicate sustained effects under treatment. These long-term effects might be explainable by soothing and protection of the irritated mucous membrane by Refluthin.<\/jats:p>","DOI":"10.1038\/s41598-025-98558-z","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T08:31:25Z","timestamp":1746606685000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prospective uncontrolled clinical study shows rapid and long lasting relief of heartburn and acid related gastric discomfort with Refluthin"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9163-5893","authenticated-orcid":false,"given":"Ahmed","family":"Madisch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Pace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Menzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Funk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berenike","family":"Stracke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christiane","family":"Sch\u00f6n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"Labenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,7]]},"reference":[{"issue":"5","key":"98558_CR1","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1136\/gut.2004.051821","volume":"54","author":"J Dent","year":"2005","unstructured":"Dent, J., El-Serag, H. B., Wallander, M. A. & Johansson, S. Epidemiology of gastro-oesophageal reflux disease: A systematic review. Gut 54(5), 710\u2013717 (2005).","journal-title":"Gut"},{"issue":"3","key":"98558_CR2","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1136\/gutjnl-2016-313589","volume":"67","author":"LH Eusebi","year":"2018","unstructured":"Eusebi, L. H. et al. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: A meta-analysis. Gut 67(3), 430\u2013440 (2018).","journal-title":"Gut"},{"issue":"11","key":"98558_CR3","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1111\/j.1365-2036.2006.02924.x","volume":"23","author":"M Nocon","year":"2006","unstructured":"Nocon, M., Keil, T. & Willich, S. N. Prevalence and sociodemographics of reflux symptoms in Germany\u2014Results from a national survey. Aliment Pharmacol Ther 23(11), 1601\u20131605 (2006).","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"98558_CR4","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1159\/000080308","volume":"22","author":"I Wiklund","year":"2004","unstructured":"Wiklund, I. Review of the quality of life and burden of illness in gastroesophageal reflux disease. Dig. Dis. 22(2), 108\u2013114 (2004).","journal-title":"Dig. Dis."},{"issue":"2","key":"98558_CR5","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1053\/j.gastro.2017.09.047","volume":"154","author":"J Tack","year":"2018","unstructured":"Tack, J. & Pandolfino, J. E. Pathophysiology of gastroesophageal reflux disease. Gastroenterology 154(2), 277\u2013288 (2018).","journal-title":"Gastroenterology"},{"issue":"1","key":"98558_CR6","doi-asserted-by":"publisher","first-page":"G117","DOI":"10.1152\/ajpgi.00134.2016","volume":"311","author":"FB van Hoeij","year":"2016","unstructured":"van Hoeij, F. B. et al. Mucosal integrity and sensitivity to acid in the proximal esophagus in patients with gastroesophageal reflux disease. Am. J. Physiol. Gastrointest. Liver Physiol. 311(1), G117\u2013G122 (2016).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"8","key":"98558_CR7","first-page":"e28563","volume":"14","author":"P Chhabra","year":"2022","unstructured":"Chhabra, P. & Ingole, N. Gastroesophageal Reflux Disease (GERD): Highlighting diagnosis, treatment, and lifestyle changes. Cureus 14(8), e28563 (2022).","journal-title":"Cureus"},{"issue":"7","key":"98558_CR8","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1055\/a-2060-1069","volume":"61","author":"A Madisch","year":"2023","unstructured":"Madisch, A. et al. S2k-Leitlinie Gastro\u00f6sophageale Refluxkrankheit und eosinophile \u00d6sophagitis der Deutschen Gesellschaft f\u00fcr Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS)\u2014M\u00e4rz 2023\u2014AWMF-Registernummer: 021\u2013013. Z Gastroenterol 61(7), 862\u2013933 (2023).","journal-title":"Z Gastroenterol"},{"issue":"6","key":"98558_CR9","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1097\/MCG.0000000000000854","volume":"51","author":"R Hunt","year":"2017","unstructured":"Hunt, R. et al. World gastroenterology organisation global guidelines: GERD global perspective on gastroesophageal reflux disease. J. Clin. Gastroenterol. 51(6), 467\u2013478 (2017).","journal-title":"J. Clin. Gastroenterol."},{"issue":"3","key":"98558_CR10","doi-asserted-by":"publisher","first-page":"300060522108645","DOI":"10.1177\/03000605221086457","volume":"50","author":"V Garg","year":"2022","unstructured":"Garg, V., Narang, P. & Taneja, R. Antacids revisited: Review on contemporary facts and relevance for self-management. J. Int. Med. Res. 50(3), 3000605221086457 (2022).","journal-title":"J. Int. Med. Res."},{"key":"98558_CR11","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.2147\/DDDT.S306371","volume":"15","author":"V Savarino","year":"2021","unstructured":"Savarino, V. et al. Pharmacological management of gastro-esophageal reflux disease: an update of the state-of-the-art. Drug Des. Dev. Ther. 15, 1609\u20131621 (2021).","journal-title":"Drug Des. Dev. Ther."},{"issue":"Suppl 4","key":"98558_CR12","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1046\/j.1365-2036.16.s4.11.x","volume":"16","author":"GN Tytgat","year":"2002","unstructured":"Tytgat, G. N. Review article: Treatment of mild and severe cases of GERD. Aliment. Pharmacol. Ther. 16(Suppl 4), 73\u201378 (2002).","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"2\u20133","key":"98558_CR13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1159\/000102627","volume":"75","author":"MC Sulz","year":"2007","unstructured":"Sulz, M. C. et al. Comparison of two antacid preparations on intragastric acidity\u2014a two-centre open randomised cross-over placebo-controlled trial. Digestion 75(2\u20133), 69\u201373 (2007).","journal-title":"Digestion"},{"key":"98558_CR14","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.carbpol.2016.09.073","volume":"157","author":"F Di Lorenzo","year":"2017","unstructured":"Di Lorenzo, F. et al. The polysaccharide and low molecular weight components of Opuntia ficus indica cladodes: Structure and skin repairing properties. Carbohydr. Polym. 157, 128\u2013136 (2017).","journal-title":"Carbohydr. Polym."},{"issue":"1","key":"98558_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0378-8741(01)00196-9","volume":"76","author":"EM Galati","year":"2001","unstructured":"Galati, E. M., Monforte, M. T., Tripodo, M. M., d\u2019Aquino, A. & Mondello, M. R. Antiulcer activity of Opuntia ficus indica (L.) Mill. (Cactaceae): ultrastructural study. J. Ethnopharmacol. 76(1), 1\u20139 (2001).","journal-title":"J. Ethnopharmacol."},{"issue":"3","key":"98558_CR16","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0378-8741(02)00243-X","volume":"83","author":"EM Galati","year":"2002","unstructured":"Galati, E. M., Pergolizzi, S., Miceli, N., Monforte, M. T. & Tripodo, M. M. Study on the increment of the production of gastric mucus in rats treated with Opuntia ficus indica (L.) Mill. cladodes. J. Ethnopharmacol. 83(3), 229\u2013233 (2002).","journal-title":"J. Ethnopharmacol."},{"issue":"4","key":"98558_CR17","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/ptr.2075","volume":"21","author":"EM Galati","year":"2007","unstructured":"Galati, E. M. et al. Opuntia ficus indica (L.) Mill mucilages show cytoprotective effect on gastric mucosa in rat. Phytother. Res. 21(4), 344\u2013346 (2007).","journal-title":"Phytother. Res."},{"issue":"1","key":"98558_CR18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/BF02975264","volume":"25","author":"EB Lee","year":"2002","unstructured":"Lee, E. B., Hyun, J. E., Li, D. W. & Moon, Y. I. Effects of Opuntia ficus-indica var. Saboten stem on gastric damages in rats. Arch. Pharm. Res. 25(1), 67\u201370 (2002).","journal-title":"Arch. Pharm. Res."},{"issue":"27","key":"98558_CR19","doi-asserted-by":"publisher","first-page":"4318","DOI":"10.3748\/wjg.v12.i27.4318","volume":"12","author":"R V\u00e1zquez-Ram\u00edrez","year":"2006","unstructured":"V\u00e1zquez-Ram\u00edrez, R., Olgu\u00edn-Mart\u00ednez, M., Kubli-Garfias, C. & Hern\u00e1ndez-Mu\u00f1oz, R. Reversing gastric mucosal alterations during ethanol-induced chronic gastritis in rats by oral administration of Opuntia ficus-indica mucilage. World J. Gastroenterol. 12(27), 4318\u20134324 (2006).","journal-title":"World J. Gastroenterol."},{"key":"98558_CR20","doi-asserted-by":"publisher","first-page":"2581461","DOI":"10.1155\/2016\/2581461","volume":"2016","author":"U Alecci","year":"2016","unstructured":"Alecci, U. et al. Efficacy and safety of a natural remedy for the treatment of gastroesophageal reflux: A double-blinded randomized-controlled study. Evid. Based Complement Alternat. Med. 2016, 2581461 (2016).","journal-title":"Evid. Based Complement Alternat. Med."},{"issue":"7","key":"98558_CR21","doi-asserted-by":"publisher","first-page":"3756","DOI":"10.1002\/ptr.7074","volume":"35","author":"GA Malfa","year":"2021","unstructured":"Malfa, G. A. et al. A standardized extract of Opuntia ficus-indica (L.) Mill. and Olea europaea L. improves gastrointestinal discomfort: A double-blinded randomized-controlled study. Phytother. Res. 35(7), 3756\u20133768 (2021).","journal-title":"Phytother. Res."},{"key":"98558_CR22","first-page":"33","volume":"5","author":"B L\u00fcttig","year":"2021","unstructured":"L\u00fcttig, B. Carbonat-Opuntia-Kombination zeigt Zweifachwirkung. Phytokompass 5, 33\u201335 (2021).","journal-title":"Phytokompass"},{"issue":"1","key":"98558_CR23","doi-asserted-by":"publisher","first-page":"22355","DOI":"10.1038\/s41598-024-74047-7","volume":"14","author":"MD Lehner","year":"2024","unstructured":"Lehner, M. D., Scheyhing, U. & Els\u00e4sser, J. A combination of carbonates and Opuntia ficus-indica extract protects esophageal cells against simulated acidic and non-acidic reflux in vitro. Sci. Rep. 14(1), 22355 (2024).","journal-title":"Sci. Rep."},{"issue":"S 01","key":"98558_CR24","first-page":"13","volume":"42","author":"Z Kulic","year":"2021","unstructured":"Kulic, Z., Weisenburger, S. & Lehner, M. D. In-vitro-charakterisierung von s\u00e4ureneutralisation und gastroprotektiver effekte einer carbonat-feigenkaktus-kombination. Z. Phytother. 42(S 01), 13 (2021).","journal-title":"Z. Phytother."},{"issue":"6","key":"98558_CR25","doi-asserted-by":"publisher","first-page":"855","DOI":"10.2165\/00003495-199957060-00003","volume":"57","author":"PN Maton","year":"1999","unstructured":"Maton, P. N. & Burton, M. E. Antacids revisited: A review of their clinical pharmacology and recommended therapeutic use. Drugs 57(6), 855\u2013870 (1999).","journal-title":"Drugs"},{"issue":"9","key":"98558_CR26","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.3109\/00365521.2013.822544","volume":"48","author":"A Ryd\u00e9n","year":"2013","unstructured":"Ryd\u00e9n, A., Denison, H., Karlsson, M. & Vakil, N. Development and validation of a patient-reported outcome instrument in partial responders to proton pump inhibitors. Scand. J. Gastroenterol. 48(9), 1018\u20131026 (2013).","journal-title":"Scand. J. Gastroenterol."},{"issue":"10","key":"98558_CR27","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1055\/a-2344-6282","volume":"62","author":"A Madisch","year":"2024","unstructured":"Madisch, A. et al. S2k guideline gastroesophageal reflux disease and eosinophilic esophagitis of the german society of gastroenterology, digestive and metabolic diseases (DGVS). Z. Gastroenterol. 62(10), 1786\u20131852 (2024).","journal-title":"Z. Gastroenterol."},{"issue":"6","key":"98558_CR28","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.gastrohep.2020.01.007","volume":"43","author":"IM Villamil Morales","year":"2020","unstructured":"Villamil Morales, I. M., Gallego Ospina, D. M. & Otero Regino, W. A. Impact of head of bed elevation in symptoms of patients with gastroesophageal reflux disease: A randomized single-blind study (IBELGA). Gastroenterol. Hepatol. 43(6), 310\u2013321 (2020).","journal-title":"Gastroenterol. Hepatol."},{"issue":"4","key":"98558_CR29","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.gastrohep.2008.12.004","volume":"32","author":"J Nuevo","year":"2009","unstructured":"Nuevo, J., Tafalla, M. & Zapardiel, J. Validation of the reflux disease questionnaire (RDQ) and gastrointestinal impact scale (GIS) in patients with gastroesophageal reflux disease in the Spanish population. Gastroenterol. Hepatol. 32(4), 264\u2013273 (2009).","journal-title":"Gastroenterol. Hepatol."},{"issue":"6","key":"98558_CR30","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jval.2016.05.007","volume":"19","author":"A Ryd\u00e9n","year":"2016","unstructured":"Ryd\u00e9n, A., Leavy, O. C., Halling, K. & Stone, A. A. Comparison of daily versus weekly recording of gastroesophageal reflux disease symptoms in patients with a partial response to proton pump inhibitor therapy. Value Health 19(6), 829\u2013833 (2016).","journal-title":"Value Health"},{"issue":"3","key":"98558_CR31","first-page":"214","volume":"115","author":"DM Clarrett","year":"2018","unstructured":"Clarrett, D. M. & Hachem, C. Gastroesophageal reflux disease (GERD). Mo Med 115(3), 214\u2013218 (2018).","journal-title":"Mo Med"},{"issue":"43","key":"98558_CR32","first-page":"86","volume":"168","author":"P Funk","year":"2023","unstructured":"Funk, P. & No\u00e9, S. Refluthin bei Sodbrennen. Pharm. Ztg. 168(43), 86\u201389 (2023).","journal-title":"Pharm. Ztg."},{"issue":"4","key":"98558_CR33","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1046\/j.1365-2036.1998.00316.x","volume":"12","author":"P Netzer","year":"1998","unstructured":"Netzer, P. et al. Comparison of the effect of the antacid Rennie versus low-dose H2-receptor antagonists (ranitidine, famotidine) on intragastric acidity. Aliment. Pharmacol. Ther. 12(4), 337\u2013342 (1998).","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"1\u20132","key":"98558_CR34","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.ijpharm.2011.11.019","volume":"422","author":"L Rizza","year":"2012","unstructured":"Rizza, L., Frasca, G., Nicholls, M., Puglia, C. & Cardile, V. Caco-2 cell line as a model to evaluate mucoprotective proprieties. Int. J. Pharm. 422(1\u20132), 318\u2013322 (2012).","journal-title":"Int. J. Pharm."},{"key":"98558_CR35","first-page":"152","volume":"2","author":"A C\u00e1rdenas","year":"1997","unstructured":"C\u00e1rdenas, A., Higuera-Ciapara, I. & Goycoolea, F. M. Rheology and aggregation of cactus (Opuntia ficus-indica) mucilage in solution. J. Prof. Assoc. Cactus Dev. 2, 152\u2013159 (1997).","journal-title":"J. Prof. Assoc. Cactus Dev."},{"key":"98558_CR36","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1055\/s-0043-1774168","volume":"89","author":"MD Lehner","year":"2023","unstructured":"Lehner, M. D. & Scheyhing, U. Opuntia ficus-indica polysaccharides protect against bile acid-induced esophageal cell irritation. Planta Med. 89, 1392 (2023).","journal-title":"Planta Med."},{"issue":"11","key":"98558_CR37","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.14309\/ajg.0000000000002360","volume":"118","author":"ES Corazziari","year":"2023","unstructured":"Corazziari, E. S. et al. Poliprotect versus omeprazole in the relief of heartburn, epigastric pain, and burning in patients without erosive esophagitis and gastroduodenal lesions: A randomized, controlled trial. Am. J. Gastroenterol. 118(11), 2014\u20132024 (2023).","journal-title":"Am. J. Gastroenterol."},{"issue":"5","key":"98558_CR38","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/apt.13914","volume":"45","author":"V Savarino","year":"2017","unstructured":"Savarino, V., Pace, F. & Scarpignato, C. Randomised clinical trial: mucosal protection combined with acid suppression in the treatment of non-erosive reflux disease\u2014efficacy of Esoxx, a hyaluronic acid-chondroitin sulphate based bioadhesive formulation. Aliment. Pharmacol. Ther. 45(5), 631\u2013642 (2017).","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"2","key":"98558_CR39","first-page":"e13056","volume":"13","author":"V Patel","year":"2021","unstructured":"Patel, V., Mehra, D., Ramirez, B., Lindo, A. & Suarez, M. Milk-alkali syndrome as a cause of hypercalcemia in a gentleman with acute kidney injury and excessive antacid intake. Cureus 13(2), e13056 (2021).","journal-title":"Cureus"},{"key":"98558_CR40","doi-asserted-by":"publisher","first-page":"6417526","DOI":"10.1155\/2018\/6417526","volume":"2018","author":"Z Khan","year":"2018","unstructured":"Khan, Z. et al. On-demand therapy with proton pump inhibitors for maintenance treatment of nonerosive reflux disease or mild erosive esophagitis: A systematic review and meta-analysis. Gastroenterol. Res. Pract. 2018, 6417526 (2018).","journal-title":"Gastroenterol. Res. Pract."},{"key":"98558_CR41","unstructured":"Hunt, R. et al. World Gastroenterology Organisation Global Guidelines. Coping with Common GI Symptoms in the Community: A Global Perspective on Heartburn, Constipation, Bloating, and Abdominal Pain\/Discomfort (2013)."},{"issue":"1","key":"98558_CR42","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/j.1365-2036.2010.04315.x","volume":"32","author":"F Cremonini","year":"2010","unstructured":"Cremonini, F. et al. Meta-analysis: The effects of placebo treatment on gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther. 32(1), 29\u201342 (2010).","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"18","key":"98558_CR43","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1001\/archinte.159.18.2161","volume":"159","author":"R Fass","year":"1999","unstructured":"Fass, R. et al. Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease. Arch. Intern. Med. 159(18), 2161\u20132168 (1999).","journal-title":"Arch. Intern. Med."},{"key":"98558_CR44","doi-asserted-by":"publisher","first-page":"44830","DOI":"10.1038\/srep44830","volume":"7","author":"P Meteerattanapipat","year":"2017","unstructured":"Meteerattanapipat, P. & Phupong, V. Efficacy of alginate-based reflux suppressant and magnesium-aluminium antacid gel for treatment of heartburn in pregnancy: A randomized double-blind controlled trial. Sci. Rep. 7, 44830 (2017).","journal-title":"Sci. Rep."},{"issue":"2","key":"98558_CR45","doi-asserted-by":"publisher","first-page":"223","DOI":"10.5056\/jnm19053","volume":"27","author":"YK Cho","year":"2021","unstructured":"Cho, Y. K. et al. Efficacy of S-pantoprazole 10 mg in the symptom control of non-erosive reflux disease: A phase III placebo-controlled trial. J. Neurogastroenterol. Motil. 27(2), 223\u2013230 (2021).","journal-title":"J. Neurogastroenterol. Motil."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-98558-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-98558-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-98558-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T09:04:50Z","timestamp":1746608690000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-98558-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,7]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["98558"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-98558-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,7]]},"assertion":[{"value":"11 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AM, FP, DM, CS, and JL have received honoraria from Dr. Willmar Schwabe GmbH & Co. KG. PF and BS are employees of Dr. Willmar Schwabe GmbH & Co. KG.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted with the approval of the Ethical Committee (Landes\u00e4rztekammer Baden-W\u00fcrttemberg, May 18, 2022; reference no. F-2022-038). It was prospectively registered at the German Clinical Trials Register (DRKS, identifier DRKS00029344) and carried out in accordance with the principles of the Declaration of Helsinki, the Professional Code for Physicians in Baden-W\u00fcrttemberg, and in orientation to the International Organisation for Standardization (ISO) 14155:2020 (Clinical investigation of medical devices for human subjects). Written informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"15896"}}